Fundraising Fox

Biotech Startups

10,099 companies tagged Biotech, with their investors and founders.

USWM Enterprises

0 investors

UVLrx Therapeutics

0 investors

V ClinBio

0 investors

Vaccinex

Vaccinex is a clinical-stage biotechnology company developing pepinemab (VX15/2503), a humanized monoclonal antibody that blocks SEMA4D signaling, in trials for neurological disorders such as Huntington's and Alzheimer's disease and for solid tumors including breast cancer, melanoma, non-small cell lung cancer and head and neck cancer. It also offers a fusion protein and ActivMab antibody discovery technology for incorporating membrane proteins such as GPCRs and ion channels into poxviruses for antibody selection.

0 investors

Vaccinogen

0 investors

VADovations

0 investors

Vaginal Biome Science

Vaginal Biome Science (VBS) is a biotechnology and R&D company developing microbiome-based diagnostics, therapeutics, and consumer care products for vaginal health, using its patented BioMatch technology and clinical research such as the VENUS Study. It serves the women's health market with clinically validated products and microbiome measurement tools.

0 investors

VAIL SCIENTIFIC, INC.

0 investors

Vala Sciences

0 investors

Valanbio Therapeutics

0 investors

ValCor Cath

0 investors

Valeritas Holdings

0 investors

Vali Nanomedical

0 investors

Valius Health

0 investors

Vantix Diagnostics

0 investors

Vapore

0 investors

Variant Pharmaceuticals

0 investors

Variation Biotechnologies (US)

0 investors

Vascarta

0 investors

Vascudyne

Vascudyne develops allograft tissue engineered from biological materials for regenerative medical applications, including heart valve therapies. The company advances non-immunogenic tissue solutions for clinical use.

0 investors

Vascular Perfusion Solutions

Vascular Perfusion Solutions develops the VP.S ENCORE, a portable cardiac perfusion system using a blood-free perfusate to extend donor heart viability up to 8 hours for transplant recovery teams. The investigational medical device is in preclinical evaluation under FDA Breakthrough Device Designation.

0 investors

Vascular Pharmaceuticals

Vascular Pharmaceuticals develops VPI-2960B, a therapeutic candidate in clinical development for diabetic nephropathy treatment. The company focuses on advancing this potential breakthrough therapy through Phase 2 trials.

0 investors

Vascular Therapies

0 investors

Vasculox

0 investors

Other sectors & tags